Navigation Links
New Drug ALT-711 decreases blood vessel stiffness

A novel drug that breaks down collagen bonds in the body's blood vessels significantly decreases the stiffness of vessels in older people, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain complications of diabetes. The drug, ALT-711, snips bonds or crosslinks created in the arteries and other tissues when glucose attaches to the protein collagen. //

Crosslinks are cable-like structures that inhibit the natural flexibility of collagen strands. They tend to proliferate with age. Crosslinks appear to toughen tissues and may contribute to some of the deterioration associated with aging and diabetes, such as elevated systolic blood pressure, stiff arteries, and impaired kidney function.

The ability to reduce vascular stiffness could have a major influence on reducing deaths from heart disease. For the current study, investigators at nine U.S. clinical centers recruited 93 people over the age of 50 who showed evidence of vascular stiffening, including high systolic blood pressure and pulse pressure of at least 60 mm Hg.

The participants were randomly divided into two groups-those who received daily doses of ALT-711 and those who were given a placebo daily. After 56 days, arterial pulse pressure - the difference between systolic and diastolic blood pressures - was significantly reduced among those taking the drug compared to the placebo group.


'"/>




Page: 1

Related medicine news :

1. Headache decreases appetite
2. Contraceptives decreases Libido
3. Alcohol decreases risk of dementia
4. Cooling decreases heart attack effects
5. Vitamin E decreases high blood pressure in kidney failure
6. Light therapy decreases depression during pregnancy
7. Perceived stress decreases vaccine response
8. Infant receives first bloodless liver transplant
9. Spouses and other partners lower blood pressure says new research
10. H2O - a cure for low blood pressure
11. Uncontrolled blood pressure
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: